Conclusions: Some things we need more info
Activity
- in primary treatment of invasive aspergillosis and in prolonged neutropenic patients
- efficacy in CNS involvement (other body sites)
- pediatric patients and neonates
- Combo?
Mechanism and development of resistance/selection
PK:
- MTD
- Importance of PK differences
Safety profile:
- CyA and caspo
- Dose adjustments in moderate/severe hepatic impairment